#### INSTITUTE

# Men's Use of Prostate Specific Antigen (PSA) Screening

Health Information National

Survey

#### **Evidence from the**

Lila J. Finney Rutten, PhD, MPH

Cancer Prevention Fellowship Program Division of Cancer Prevention National Cancer Institute (NCI), MD, USA

nts




Helen I Meissner, PhD, ScM Barbara K Rimer, DrPH Nancy Breen, PhD NCI, MD, USA UNC at Chapel Hill, NC, USA NCI, MD, USA



### Screening Uptake

Recent Use of Cancer Screening Tests: 1987, 1992, 1998, 2000



Source: NHIS. Percentages are standardized to the 2000 Projected U.S. Population by 5-year age groups. **PAP smear**: Within the last 3 years, age 25+. **Mammogram**: Within the last 2 years, age 40+. **FOBT**: Fecal Occult Blood Test within the last year, age 50+. **CRE**: Colorectal endoscopy within the last 3 years, age 50+. **PSA**: Prostate Specific Antigen test within the past year, age 50+. Source: Swan J et al, *Cancer*, 2003

### PSA Screening Controversy

#### Potential Benefits



#### Potential Harms

- Early detection
- Treatment may be effective
- May contribute to the declining mortality; insufficient evidence

- False positives
- Diagnosis of clinically insignificant cancers
- Treatment side effects

<sup>1</sup> Slide adapted from Sharing the Decision: Screening for Prostate Cancer (CDC)

### Evidence to Support Screening

US Preventive Services Task Force review of evidence

 On-going randomized controlled trials
 European Randomized Study of Screening for Prostate Cancer
 U.S. National Cancer Institute Prostate, Lung, Colorectal and Ovarian Trial

### **Screening Recommendations**

**U.S. Preventive Services Task Force American Cancer Society American Academy of Family Physicians** American College of Physicians/American **Society of Internal Medicine American College of Preventive Medicine American Medical Association** 

### Medical Decision Making

#### Patient understanding and decision making

Models of medical decision making

Shared Decision Making (SDM)
Informed Decision Making (IDM)



Briss et al, 2004 ;Sheridan et al., 2004

### IDM and SDM

**Understand the disease** 

**Comprehend available clinical services** 

risks & benefits

limitations & uncertainties

alternatives

**Consider personal preferences** 

**Preferred level of participation in decision-making** 

**Decision consistent with personal preferences** 

IDM: Any intervention in communities or healthcare systems intended to promote informed decisions

SDM: informed decision making interventions in clinical settings in which both patients and providers express preferences and participate in decision making

Figure used with thanks to the CDC Community Preventive Services Task Force

### Study Objectives

- 1. PSA use among US men
- 2. PSA use among subgroups
- 3. Association between PSA use and factors relevant to SDM/IDM:
  - Health information attention/seeking
  - Perceptions of provider behavior
    - explain
    - involve
    - recommend






Computer-Assisted Telephone Interview Random Digit Dial (RDD) National probability sample of adult population (18+) Surveillance and research vehicle Repeated cyclically to track trends

Slide adapted from HINTS briefing to the NCI director (Hesse, 2003)

### **Conceptual Framework**

#### **Consumer-Oriented Health Communication**




Formal (e.g. physicians) Informal (e.g. family) Commercial (e.g. media)

### **Sample Characterstics**

Sub-Sample (n=927) Men Aged 50+ No history of prostate cancer Complete Interview

### **Survey Content**



### **Survey Content (communication)**

Perceived Provider Behavior

**SDM** 

Explain clearly Involve in decisions Recommend PSA

Global

Information Attend/Seek

**IDM** 

Attend to health/medical information: TV Radio Newspapers Magazines Internet

Sought cancer information



SUDAAN **Bivariate analyses Crosstabulations and Chi-Square Correlation Multivariate analyses** Logistic regression **Sociodemographics PSA Screening** Health care access Information attend/seek (IDM) **Perceived Provider Behavior (SDM) Explain** Involve Recommend

# **Sociodemographic Characteristics**

	Ever H	ad PSA	Never I	lad PSA	
Age	Ν	%	Ν	%	
50-64	286	<b>49.7</b>	263	50.3	
65-74	155	<b>67.9</b>	64	32.1	
75+	74	57.6	52	42.4	
<b>Race/Ethnicity</b>					
White, non-Hispanic	426	<b>58.7</b>	274	41.3	
Black, non-Hispanic	44	52.0	37	48.0	
Hispanic	18	26.4	41	73.6	
Non-Hispanic Other	12	34.2	20	65.7	

# **Sociodemographic Characteristics**

	Ever H	<b>Ever Had PSA</b>		Had PSA	
	Ν	%	Ν	%	
Income					
<u>&lt;</u> 25,000	<b>88</b>	37.4	135	62.6	
>25,000 to <50,000	146	57.5	105	42.5	
<u>≥</u> 50,000	234	63.5	114	33.6	
Education					
< High school	41	38.9	81	61.1	
High school graduate	122	<b>48.9</b>	128	51.1	
Some college	114	<b>57.0</b>	80	43.0	
College graduate	238	72.3	89	27.7	

### **Health Care Access**

	Ever H	lad PSA	Never	Had PSA	
	Ν	0/0	Ν	%	
Insurance					
Yes	501	58.3	325	41.7	
No	14	17.9	54	82.2	
Usual Source of Care					
Yes	439	61.9	239	38.1	
No	74	32.8	140	67.2	

All  $\approx$  2 for crosstabs of ever/never had PSA with sociodemographic and health care access variables significant at p<01.

## **Communication**

	Ever Had	PSA	Never	Had PSA
	Ν	%	Ν	%
Received				
Recommendation				
Yes	384	75.9	5	1.6
No	125	24.1	374	98.45
æ² (1)=603.2, p<.0001				

	Ν	r	p-value	
Perceived				
<b>Provider Behavior</b>				
Explain	748	.05	0.17	
Involve	746	.13	0.0004	
Information				
Attend/Seek	884	.23	0.0000	

### Logistic Model

### Predictors



### Outcome


Ever Had PSA



	OR	95% CI
Age		
50 to 64	1.00	1.00-1.00
65 to 74	2.53	1.49-4.31
75 plus	1.50	0.84-2.68
Race/Ethnicity		
White, non-Hispanic	1.00	1.00-1.00
Black, non-Hispanic	0.94	0.47-1.87
Hispanic	0.51	0.21-1.24
Other, non-Hispanic	0.38	0.14-1.03
Education		
<hs< td=""><td>1.00</td><td>1.00-1.00</td></hs<>	1.00	1.00-1.00
HS	1.78	0.94-3.40
Some College	2.41	1.22-4.77
College Graduate	5.01	2.53-9.90



	OR	95% CI
Health Insurance		
Yes	1.00	1.00-1.00
No	0.32	0.12-0.88
<b>Usual Source of Care</b>		
Yes	1.00	1.00-1.00
No	0.35	0.22-0.54




	OR	95% CI
Age		
50 to 64	1.00	
65 to 74	2.60	1.19-5.66
75 plus	2.12	0.74- 6.13
Race/Ethnicity		
non-Hispanic white	1.00	
non-Hispanic black	0.57	0.17-1.86
Hispanic	0.65	0.07-5.76
non-Hispanic other	0.26	0.06-1.18
Education		
<hs< td=""><td>1.00</td><td></td></hs<>	1.00	
HS	1.59	0.39-6.48
Some College	2.19	0.42-11.32
College Graduate	4.47	0.99-20.29

	OR	<u>95% CI</u>
Health Insurance		
Yes	1.00	
No	0.18	0.01-2.68
<b>Usual Source of Care</b>		
Yes	1.00	
No	0.64	0.29-1.38
Information		
Attention/Seeking	1.03	0.84-1.27
<b>Perceived Provider Behavior</b>		
Explain	0.65	0.38-1.12
Involve	1.76	1.02-3.03
Recommend	236.25	70.53-791.38

### Summary of Initial Analyses


Age Involve PSA Screening Recommend

Important role of health care providers Patient involvement in decision making



	OR	95% CI
Δσο		
Age	1 00	
50 to 64	1.00	
65 to 74	2.30	1.33-4.00
75 plus	1.46	0.77- 2.76
Race/Ethnicity		
non-Hispanic white	1.00	
non-Hispanic black	1.19	0.54-2.61
Hispanic	0.51	0.22-1.19
non-Hispanic other	0.39	0.12-1.22
Education		
<hs< td=""><td>1.00</td><td></td></hs<>	1.00	
HS	1.51	0.77-2.96
Some College	1.64	0.83-3.22
College Graduate	2.91	1.45-5.82

	OR	<u>95% CI</u>
Health Insurance		
Yes	1.00	
No	0.45	0.14-1.46
<b>Usual Source of Care</b>		
Yes	1.00	
No	0.37	0.22-0.64
Information		
Attention/Seeking	1.23	1.07-1.40
<b>Perceived Provider Behavior</b>		
Explain	0.91	0.63-1.31
Involve	1.16	0.86-1.57



	OR	95% CI
Age		
50 to 64	1.00	
65 to 74	0.72	0.45-1.17
75 plus	0.94	0.47- 1.88
Race/Ethnicity		
non-Hispanic white	1.00	
non-Hispanic black	2.29	0.66-7.79
Hispanic	0.40	0.19-0.85
non-Hispanic other	0.99	0.25-4.00
Education		
<hs< td=""><td>1.00</td><td></td></hs<>	1.00	
HS	0.58	0.32-1.05
Some College	0.56	0.24-1.28
College Graduate	1.04	0.58-1.87

	OR	95% CI
Health Insurance		
Yes	1.00	
No	0.32	0.10-1.07
<b>Usual Source of Care</b>		
Yes	1.00	
No	0.38	0.20-0.71
Information		
Attention/Seeking	1.08	0.94-1.25

### <u>Conclusions</u>

- HINTS provides a unique opportunity to explore the relationship of communication variables with PSA screening
- The controversy surrounding PSA screening underscores the importance of IDM and SDM
- Many questions about patient and provider responsibility and accountability for screening decisions remain